Request for BD FACSAria Fusion Cell Sorter ShEEP Application

请求 BD FACSAria 融合细胞分选仪 SheEEP 申请

• 批准号: 9905139
• 负责人: Michal A Olszewski
• 金额: --
• 依托单位: VETERANS HEALTH ADMINISTRATION
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-01 至 2020-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9905139
• 关键词: Adoptive Cell Transfers; Adoptive Transfer; Affect; Animals; Antigens; Applications Grants; Award; Bacterial Pneumonia; Behavior; Biological Assay; Biological Markers; Biological Sciences; Biology; Biomedical Engineering; Biomedical Research; CD4 Positive T Lymphocytes; CD8-Positive T-Lymphocytes; Cancer Biology; Cell Separation; Cell Survival; Cell fusion; Cells; Central Nervous System Infections; Chronic Obstructive Airway Disease; Chronic lung disease; Clinical; Collaborations; Collection; Communicable Diseases; Complex; Complex Mixtures; Data; Data Analyses; Data Collection; Dendritic Cells; Development; Disease; Disease model; Drug Implants; Ensure; Equipment; Faculty; Faculty Recruitment; Flow Cytometry; Fluorescence; Funding; Future; Genes; Genetic Transcription; Genomics; Gold; Health; Health Care Research; Healthcare Systems; Immune; Immune System Diseases; Immune system; Immunology; Immunosuppression; Immunotherapeutic agent; In Vitro; Individual; Investigation; Laboratories; Learning; Lung diseases; Malignant - descriptor; Malignant Neoplasms; Methods; Microglia; Minor; Molecular; Natural Killer Cells; Neurodegenerative Disorders; Pathogenesis; Pathology; Patients; Pattern; Physiology; Population; Process; Proteomics; RNA; Research; Research Activity; Research Personnel; Sampling; Services; Sheep; Site; Solid; Sorting - Cell Movement; Specificity; Specimen; Stains; Sterility; Students; Subgroup; System; Techniques; Technology; Testing; Therapeutic Intervention; Time; Tissues; Traumatic CNS injury; Tumor Stem Cells; Veterans; Viral Pneumonia; base; cell type; cost; design; experimental study; high risk; implantable device; improved; instrument; leukemia; macrophage; neoantigens; neoplasm immunotherapy; neuropathology; neutrophil; new technology; new therapeutic target; novel; novel marker; novel strategies; oncology; population based; pre-clinical therapy; programs; response; single cell sequencing; single-cell RNA sequencing; therapeutic target; training opportunity; transcriptome; translational study; vector

This proposal is for a high capacity flow cytometry sorter BD FACSAria Fusion Cell Sorter to allow 6 Major Users (Merit Award funded PIs) and 7 Minor Users at the VA Ann Arbor Health Care System (VAAAHS) to conduct Multi-parameter flow cytometry cell sorting to isolate highly purified cell subsets for subsequent analysis, experimental manipulations, and studies. Our research focuses on cellular and molecular mechanisms of diseases that preferentially affect veterans: COPD, neurodegenerative disorders and CNS trauma, solid cancers and leukemias, the deployment-related lung disease and group of infectious complications for which veterans have higher risk. Involvement of specific and frequently rare cell subsets and their unique responses are increasingly found to influence these conditions and need to be studied. New experimental approaches, such as single-cell RNA sequencing, cellular vector deliveries for immunotherapeutic approaches, and adoptive transfers, all rely on high-purity cell sorting that must be performed rapidly, precisely, and aseptically to acquire specific cell populations with high viability. These needs are not being adequately met at the VAAAHS. Requested FACS sorter, presently unavailable at our VA station, will allow for collection of rare cell populations based on their expression of a unique set of multiple specific markers that would otherwise be impossible or very difficult to obtain. The high capacity sorter will allow for sorting in a timely fashion (to maintain cell viability, sterility and unaltered activation state) while working on multiple samples. Our diverse group of users will be able to 1) effectively collect quantitative data from small and precious samples; 2) use of highly specific subsets of cells in further assays like RNA transcriptome analysis, single-cell sequencing, proteomics, gene array analysis, etc; 3) generate cells for adoptive transfer experiments and preclinical therapy tests; 4) isolate and study purified cell subsets from clinical samples and implanted devices to discover new biomarkers, therapeutic targets, and to advance design of therapeutic implants. Introducing these new capabilities will enhance quality of current studies and increase efficiency and throughput. It will also enhance future grant applications of our faculty and create new learning opportunities for trainees at the VAAAHS site to ultimately benefit Veterans’ health.

该提议是针对高容量流式细胞仪分类器BD FACSARIA融合细胞分系程序的 允许弗吉尼亚州Ann Arbor Health的6个主要用户（优异奖资助的PIS）和7位未成年人用户 护理系统（VAAAHS）进行多参数流式细胞仪细胞分类以高度分离 纯化的细胞子集，以进行后续分析，实验操作和研究。我们的 研究重点是优先影响疾病的细胞和分子机制 退伍军人：COPD，神经退行性疾病和CNS创伤，固体癌和白血病， 与部署相关的肺部疾病和退伍军人的感染并发症组 风险更高。参与特定且经常稀有的细胞子集及其独特 越来越多地发现反应会影响这些条件，需要研究。新的 实验方法，例如单细胞RNA测序，细胞矢量递送 免疫治疗方法和自适应转移都依赖于高纯度细胞分类 必须迅速，精确和美观地执行以获取特定的细胞群体 高活性。这些需求在VAAAHS上没有得到充分满足。请求的是 目前在我们的VA站无法使用的分类器将允许收集稀有的细胞种群 基于它们表达了一组独特的多个特定标记，否则 不可能或很难获得。高容量分落者将允许及时排序 时尚（维持细胞的生存力，不育和未改变的激活状态） 多个样本。我们的潜水员组将能够1）有效收集定量 来自小样品的数据； 2）在进一步的测定中使用高度特定的细胞子集 例如RNA转录组分析，单细胞测序，蛋白质组学，基因阵列分析等； 3） 生成用于自适应转移实验和临床前治疗测试的细胞； 4）分离和 从临床样品和植入设备中研究纯化的细胞子集，以发现新的细胞集 生物标志物，治疗靶标，并提高治疗性染色的设计。介绍 这些新功能将提高当前研究的质量并提高效率和 吞吐量。它还将增强我们教师的未来赠款应用，并创建新的学习 VAAAHS网站的受训者的机会最终使退伍军人健康受益。